Docetaxel enhances CD3 + CD56 + cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation

Biomedicine and Pharmacotherapy

Volumn 69, Issue , 2015, Pages 18-23

  Wang, WenJia ^a   Qin, SiHao ^b   Zhao, Lei ^a  

^a JILIN UNIVERSITY   (China)

^b YANBIAN UNIVERSITY   (China)

Author keywords

Calreticulin; Cytokine induced killer cells; Docetaxel; Immunogenic modulation

Indexed keywords

BLOCKING ANTIBODY; CALRETICULIN; CD3 ANTIGEN; CD56 ANTIGEN; DOCETAXEL; DOXORUBICIN; INTERCELLULAR ADHESION MOLECULE 1; SMALL INTERFERING RNA; TAXOID;

ADENOCARCINOMA CELL LINE; ARTICLE; CELL DEATH; CELL KILLING; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOLYSIS; DOSE RESPONSE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOMODULATION; IN VITRO STUDY; LUNG ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL; UPREGULATION; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; IMMUNOLOGY; KINETICS; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD3; ANTIGENS, CD56; CALRETICULIN; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; KINETICS; NEOPLASMS; PHENOTYPE; TAXOIDS; UP-REGULATION;

EID: 84922259961     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.10.026     Document Type: Article

References (33)

1. Vasekar M., Liu X., Zheng H., Belani C.P. Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol 2014, 5:39-47.
2. Zhao M., Li H., Li L., Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytokine-induced killer immunotherapy on recurrence and survival rate of non-small cell lung cancer patients. Exp Ther Med 2014, 7:1403-1407.
3. Zhao L., Wang W.J., Zhang J.N., Zhang X.Y. 5-fluorouracil and interleukin-2 Immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev 2014, 15:4039-4044.
4. Shi S., Wang R., Chen Y., Song H., Chen L., Huang G. Combining antiangiogenic therapy with adoptive cell immunotherapy exerts better antitumor effects in non-small cell lung cancer models. PLoS One 2013, 8:e65757.
5. Chen Y., Lin G., Guo Z.Q., Zhou Z.F., He Z.Y., Ye Y.B. Effects of MICA expression on the prognosis of advanced non-small cell lung cancer and the efficacy of CIK therapy. PLoS One 2013, 8:e69044.
6. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+ CD56+ CIK cells, a T cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
7. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
8. Zitvogel L., Kepp O., Senovilla L., Menger L., Chaput N., Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16:3100-3104.
9. Gameiro S.R., Higgins J.P., Dreher M.R., Woods D.L., Reddy G., Wood B.J., et al. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One 2013, 8:e70417.
10. Gameiro S.R., Jammeh M.L., Wattenberg M.M., Tsang K.Y., Ferrone S., Hodge J.W. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T cell killing. Oncotarget 2014, 5:403-416.
11. Talme T., Bergdahl E., Sundqvist K.G. Regulation of T-lymphocyte motility, adhesion and de-adhesion by a cell-surface mechanism directed by low-density lipoprotein receptor-related protein 1 and endogenous thrombospondin-1. Immunology 2014, 142:176-192.
12. Lacroix M., Dumestre-Perard C., Schoehn G., Houen G., Cesbron J.Y., Arlaud G.J., et al. Residue Lys57 in the collagen-like region of human L-ficolin and its counterpart Lys47 in H-ficolin play a key role in the interaction with the mannan-binding lectin-associated serine proteases and the collectin receptor calreticulin. J Immunol 2009, 182:456-465.
13. Yao L., Pike S.E., Tosato G. Laminin binding to the calreticulin fragment vasostatin regulates endothelial cell function. J Leukoc Biol 2002, 71:47-53.
14. Nde P.N., Lima M.F., Johnson C.A., Pratap S., Villalta F. Regulation and use of the extracellular matrix by Trypanosoma cruzi during early infection. Front Immunol 2012, 3:337.
15. Hodge J.W., Kwilas A., Ardiani A., Gameiro S.R. Attacking malignant cells that survive therapy: exploiting immunogenic modulation. Oncoimmunology 2013, 2:e26937.
16. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009, 37:616-628. [e2].
17. Shi S., Tao L., Song H., Chen L., Huang G. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice. APMIS 2014, 122:380-391.
18. Kim J.S., Park Y.S., Kim J.Y., Kim Y.G., Kim Y.J., Lee H.K., et al. Inhibition of human pancreatic tumor growth by cytokine-induced killer cells in nude mouse xenograft model. Immune Netw 2012, 12:247-252.
19. Ma Y., Xu Y.C., Tang L., Zhang Z., Wang J., Wang H.X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 2012, 1:11.
20. Jiang J., Wu C., Lu B. Cytokine-induced killer cells promote antitumor immunity. J Transl Med 2013, 11:83.
21. Tao L., Huang G., Shi S., Chen L. Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models. Med Oncol 2014, 31:777.
22. Wu C., Jiang J., Shi L., Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008, 28:3997-4002.
23. Huang X., Chen Y.T., Song H.Z., Huang G.C., Chen L.B. Cisplatin pretreatment enhances antitumor activity of cytokine-induced killer cells. World J Gastroenterol 2011, 17:3002-3011.
24. Brenner C., Galluzzi L., Kepp O., Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol 2013, 59:583-594.
25. Rzepecka J., Rausch S., Klotz C., Schnoller C., Kornprobst T., Hagen J., et al. Calreticulin from the intestinal nematode Heligmosomoides polygyrus is a Th2-skewing protein and interacts with murine scavenger receptor-A. Mol Immunol 2009, 46:1109-1119.
26. Duo C.C., Gong F.Y., He X.Y., Li Y.M., Wang J., Zhang J.P., et al. Soluble calreticulin induces tumor necrosis factor-alpha (TNF-alpha) and interleukin (IL)-6 production by macrophages through mitogen-activated protein kinase (MAPK) and NFkappaB signaling pathways. Int J Mol Sci 2014, 15:2916-2928.
27. Ghiran I., Klickstein L.B., Nicholson-Weller A. Calreticulin is at the surface of circulating neutrophils and uses CD59 as an adaptor molecule. J Biol Chem 2003, 278:21024-21031.
28. Vance B.A., Harley P.H., Backlund P.S., Ward Y., Phelps T.L., Gress R.E. Human CD69 associates with an N-terminal fragment of calreticulin at the cell-surface. Arch Biochem Biophys 2005, 438:11-20.
29. Goere D., Flament C., Rusakiewicz S., Poirier-Colame V., Kepp O., Martins I., et al. Potent immunomodulatory effects of the trifunctional antibody catumaxomab. Cancer Res 2013, 73:4663-4673.
30. Pawaria S., Binder R.J. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2011, 2:521.
31. Nilsson A., Vesterlund L., Oldenborg P.A. Macrophage expression of LRP1, a receptor for apoptotic cells and unopsonized erythrocytes, can be regulated by glucocorticoids. Biochem Biophys Res Commun 2012, 417:1304-1309.
32. Chen D., Texada D.E., Duggan C., Liang C., Reden T.B., Kooragayala L.M., et al. Surface calreticulin mediates muramyl dipeptide-induced apoptosis in RK13 cells. J Biol Chem 2005, 280:22425-22436.
33. Hodge J.W., Garnett C.T., Farsaci B., Palena C., Tsang K.Y., Ferrone S., et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T-lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013, 133:624-636.